Aktiia focuses on continuous and accurate blood pressure monitoring to address the global challenge of hypertension, which affects over 1.4 billion people and contributes to more than 18 million deaths annually. Founded on two decades of research, Aktiia's innovative technology combines optical sensors with clinically validated software algorithms to provide personalized, medical-grade blood pressure and heart rate data. This continuous monitoring enables individuals, researchers, and clinicians to gain deeper insights into hypertension, fostering more effective and personalized patient care. By improving accessibility and accuracy in blood pressure management, Aktiia aims to change the approach to this critical health issue, ultimately enhancing the understanding and treatment of high blood pressure.
Aktiia focuses on continuous and accurate blood pressure monitoring to address the global challenge of hypertension, which affects over 1.4 billion people and contributes to more than 18 million deaths annually. Founded on two decades of research, Aktiia's innovative technology combines optical sensors with clinically validated software algorithms to provide personalized, medical-grade blood pressure and heart rate data. This continuous monitoring enables individuals, researchers, and clinicians to gain deeper insights into hypertension, fostering more effective and personalized patient care. By improving accessibility and accuracy in blood pressure management, Aktiia aims to change the approach to this critical health issue, ultimately enhancing the understanding and treatment of high blood pressure.
MultiOmic Health
Seed Round in 2023
MultiOmic Health is an AI-driven start-up specializing in drug discovery for metabolic syndrome-related diseases. The company collaborates with selected healthcare providers to collect and analyze de-identified patient data and bio-samples. Its MOHSAIC® platform integrates multi-omics analysis with computational systems biology modeling and targeted laboratory experiments to develop novel precision therapeutic concepts. These concepts are then commercialized through partnerships with established biopharma companies, facilitating the creation of new therapeutic and diagnostic research and development programs. By focusing on precision medicine, MultiOmic Health aims to improve treatment options for patients suffering from metabolic syndrome.
Sleepiz AG, based in Zurich, Switzerland, specializes in manufacturing a non-contact sleep monitoring device aimed at enhancing healthcare accessibility in home environments. Incorporated in 2018, the company's innovative product is designed to be placed on a bedside table, where it accurately measures patients' breathing patterns, heart rate, and body movements using advanced wireless millimeter wave technology and artificial intelligence. This device not only facilitates the diagnosis of sleep disorders but also enables long-term monitoring of chronic diseases, allowing healthcare providers to track patient progression and implement timely interventions for improved treatment outcomes. Through its user-friendly and precise approach, Sleepiz is positioned to significantly contribute to patient-centric disease management.
Aktiia focuses on continuous and accurate blood pressure monitoring to address the global challenge of hypertension, which affects over 1.4 billion people and contributes to more than 18 million deaths annually. Founded on two decades of research, Aktiia's innovative technology combines optical sensors with clinically validated software algorithms to provide personalized, medical-grade blood pressure and heart rate data. This continuous monitoring enables individuals, researchers, and clinicians to gain deeper insights into hypertension, fostering more effective and personalized patient care. By improving accessibility and accuracy in blood pressure management, Aktiia aims to change the approach to this critical health issue, ultimately enhancing the understanding and treatment of high blood pressure.
Sleepiz AG, based in Zurich, Switzerland, specializes in manufacturing a non-contact sleep monitoring device aimed at enhancing healthcare accessibility in home environments. Incorporated in 2018, the company's innovative product is designed to be placed on a bedside table, where it accurately measures patients' breathing patterns, heart rate, and body movements using advanced wireless millimeter wave technology and artificial intelligence. This device not only facilitates the diagnosis of sleep disorders but also enables long-term monitoring of chronic diseases, allowing healthcare providers to track patient progression and implement timely interventions for improved treatment outcomes. Through its user-friendly and precise approach, Sleepiz is positioned to significantly contribute to patient-centric disease management.
Humanoo is a digital health platform aimed at enhancing the physical and mental well-being of employees and insurance clients. The platform offers customized programs and innovative eHealth solutions in areas such as fitness, physiotherapy, yoga, mindfulness, and nutrition, helping users achieve their health goals. By providing comprehensive decentralized analysis, Humanoo enables companies and insurers to gain insights into the health of their employees or clients, facilitating measurable improvements. The team, comprised of 65 professionals from 15 countries, includes software developers, designers, marketing and sales specialists, as well as health and wellness experts such as sports scientists, nutritionists, yoga instructors, and physiotherapists. Humanoo's mission is to motivate individuals to maintain a healthy lifestyle and improve their overall productivity.
Pregnolia
Series A in 2020
Pregnolia ensures that every woman can have a happy, healthy and informed pregnancy until term. Their team knows that the existing research about preterm birth assessment is very promising, but this alone does not guarantee success. Sabrina, Francisco and Annette are highly committed to develop the commercial version of the device, complete the clinical trial, follow the regulatory roadmap and execute on their business vision to successfully support gynaecologists in improving the preterm birth risk assessment and birth management.
Aktiia focuses on continuous and accurate blood pressure monitoring to address the global challenge of hypertension, which affects over 1.4 billion people and contributes to more than 18 million deaths annually. Founded on two decades of research, Aktiia's innovative technology combines optical sensors with clinically validated software algorithms to provide personalized, medical-grade blood pressure and heart rate data. This continuous monitoring enables individuals, researchers, and clinicians to gain deeper insights into hypertension, fostering more effective and personalized patient care. By improving accessibility and accuracy in blood pressure management, Aktiia aims to change the approach to this critical health issue, ultimately enhancing the understanding and treatment of high blood pressure.
Pregnolia
Seed Round in 2018
Pregnolia ensures that every woman can have a happy, healthy and informed pregnancy until term. Their team knows that the existing research about preterm birth assessment is very promising, but this alone does not guarantee success. Sabrina, Francisco and Annette are highly committed to develop the commercial version of the device, complete the clinical trial, follow the regulatory roadmap and execute on their business vision to successfully support gynaecologists in improving the preterm birth risk assessment and birth management.
DomoHealth
Series A in 2016
Domo Health is a Swiss company transforming healthcare through its innovative digital health platform that connects patients to their local care environment. Powered by real-world data and AI, we enhance personalized and preventive care at home. With our SaaS clinical platform, domo.health, we monitor patients' conditions, offer safety solutions, and empower professionals to make informed decisions. Together, we're shaping a future focused on safer and healthier in-home experiences.
DomoHealth
Seed Round in 2016
Domo Health is a Swiss company transforming healthcare through its innovative digital health platform that connects patients to their local care environment. Powered by real-world data and AI, we enhance personalized and preventive care at home. With our SaaS clinical platform, domo.health, we monitor patients' conditions, offer safety solutions, and empower professionals to make informed decisions. Together, we're shaping a future focused on safer and healthier in-home experiences.
DomoHealth
Angel Round in 2012
Domo Health is a Swiss company transforming healthcare through its innovative digital health platform that connects patients to their local care environment. Powered by real-world data and AI, we enhance personalized and preventive care at home. With our SaaS clinical platform, domo.health, we monitor patients' conditions, offer safety solutions, and empower professionals to make informed decisions. Together, we're shaping a future focused on safer and healthier in-home experiences.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.